Class II MHC genes: A model gene regulatory system with great biologic consequences

Microbes and Infection

Volumn 1, Issue 11, 1999, Pages 855-861

  Pan Yun Ting, Jenny ^a   Zhu, Xin Sheng ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; RECEPTOR OCCUPANCY; REGULATOR GENE; REVIEW; TRANSCRIPTION REGULATION;

EID: 0344286550     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)00233-6     Document Type: Article

References (54)

1. Baxevanis A.D., Arents G., Moudrianakis E.N., Landsman D. A variety of DNA-binding and multimeric proteins contain the histone fold motif. Nucleic Acids Res. 23:1995;2685-2691.
2. Benoist C., Mathis D. Regulation of major histocompatibility complex class-II genes: X Y and other letters of the alphabet. Ann. Rev. Immunol. 8:1990;681-715.
3. Busch R., Mellins E.D. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr. Opin. Immunol. 8:1996;51-58.
4. Chang C.H., Fontes J.D., Peterlin M., Flavell R.A. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J. Exp. M. 180:1994;1367-1374.
5. Chin K.C., Li G.X., Ting J.P.Y. Importance of acidic proline/serine/threonine-rich and GTP-binding regions in the major histocompatibility complex class II transactivator: Generation of transdominant-negative mutants. Proc. Natl. Acad. Sci. USA. 94:1997;2501-2506.
6. Chin K.C., Mao C., Skinner C., Riley J.L., Wright K.L., Moreno C.S., Stark G.R., Boss J.M., Ting J.P.Y. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity. 1:1994;687-697.
7. Collinge M., Pardi R., Bender J.R. Class II transactivator-independent endothelial cell MHC class II gene activation induced by lymphocyte adhesion. J. Immunol. 161:1998;1589-1593.
8. Cressman D.E., Chin K.C., Taxman D.J., Ting J.P. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. Immunity. 10:1999;163-171.
9. Cresswell P. Invariant chain structure and MHC class II function. Cell. 84:1996;505-507.
10. Currie R.A. NF-Y is associated with the histone acetyltransferases GCN5 and P/CAF. J. Biol. Chem. 273:1998;1430-1434.
11. Didier D.K., Schiffenbauer J., Woulfe S.L., Zacheis M., Schwartz B.D. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc. Natl. Acad. Sci. USA. 85:1988;7322-7326.
12. Durand B., Sperisen P., Emery P., Barras E., Zufferey M., Mach B., Reith W. RFXAP a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 16:1997;1045-1055.
13. Fontes J.D., Jabrane-Ferrat N., Toth C.R., Peterlin B.M. Binding and cooperative interactions between two B cell-specific transcriptional coactivators. J. Exp. M. 183:1996;2517-2521.
14. Fontes J.D., Jiang B., Peterlin B.M. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. Nucleic Acids Res. 25:1997;2522-2528.
15. Fontes J.D., Kanazawa S., Jean D., Peterlin B.M. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol. Cell Biol. 19:1999;941-947.
16. Gaur L.K., Heise E.R., Ting J.P. Conservation of the promoter region of DRA-like genes from nonhuman primates. Immunogenetics. 35:1992;136-139.
17. Jin S., Scotto K.W. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell Biol. 18:1998;4377-4384.
18. Kara C.J., Glimcher L.H. In vivo footprinting of MHC class II genes: Bare promoter in the Bare Lymphocyte Syndrome. Science. 252:1991;709-712.
19. Kretsovali A. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator. Mol. Cell Biol. 18:1998;6777-6783.
20. Kropshofer H., Arndt S.O., Moldenhauer G., Hammerling G.J., Vogt A.B. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity. 6:1997;293-302.
21. Li Q., Herrler M., Landsberger N., Kaludov N., Ogryzko V.V., Nakatani Y., Wolffe A.P. Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. EMBO J. 17:1998;6300-6315.
22. Linhoff M.W., Wright K.L., Ting J.P.Y. CCAAT-binding factor NF-Y and RFX are required for in vivo assembly of a nucleoprotein complex that spans 250 base pairs: the invariant chain promoter as a model. Mol. Cell Biol. 17:1997;4589-4596.
23. Lloberas J., Soler C., Celada A. Repression mechanisms of the I-A beta gene of the major histocompatibility complex. Immunobiology. 198:1997;249-263.
24. MacDonald G.H., ItohLindstrom Y., Ting J.P. The transcriptional regulatory protein YB-1 promotes single-stranded regions in the DRA promoter. J. Biol. Chem. 270:1995;3527-3533.
25. Maity S.N., Sinha S., Ruteshouser E.C., DeCrombrugghe B. Three different polypeptides are necessary for DNA binding of mammalian heteromeric CCAAT binding factor. J. Biol. Chem. 267:1992;16574-16580.
26. Mantovani R., Pessara U., Tronche F., Li X.Y., Knapp A.M., Pasquali J.L., Benoist C., Mathis D. Monoclonal antibodies to NF-Y define its function in MHC class II and albumin gene transcription. EMBO J. 11:1992;3315-3322.
27. Masternak K., Barras E., Zufferey M., Conrad B., Corthals G., Aebersold R., Sanchez J.C., Hochstrasser D.F., Mach B., Reith W. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat. Genet. 20:1998;273-277.
28. Montani V., Taniguchi S.I., Shong M., Suzuki K., Ohmori M., Giuliani C., Napolitano G., Saji M., Fiorentino B., Reimold A.M., Ting J.P., Kohn L.D., Singer D.S. Major histocompatibility class II HLA-DR alpha gene expression in thyrocytes: counter regulation by the class II transactivator and the thyroid Y box protein. Endocrinology. 139:1998;280-289.
29. Moreno C.S., Beresford G.W., Louis-Plence P., Morris A.C., Boss J.M. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity. 10:1999;143-151.
30. Motta M.C., Caretti G., Badaracco G.F., Mantovani R. Interactions of the CCAAT-binding trimer NF-Y with nucleosomes. J. Biol. Chem. 274:1999;1326-1333.
31. Muhlethaler-Mottet A., DiBerardino W., Otten L.A., Mach B. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity. 8:1998;157-166.
32. Piskurich J.F., Linhoff M.W., Wang Y., Ting J.P.Y. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1 interferon regulatory factor 1 and transforming growth factor beta. Mol. Cell Biol. 19:1999;431-440.
33. Piskurich J.F., Wang Y., Linhoff M.W., White L.C., Ting J.P. Identification of distinct regions of 5' flanking DNA that mediate constitutive IFN-gamma STAT1 and TGF-beta-regulated expression of the class II transactivator gene. J. Immunol. 160:1998;233-240.
34. Reith W., Siegrist C.A., Durand B., Barras E., Mach B. Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y. Proc. Natl. Acad. Sci. USA. 91:1994;554-558.
35. Rigaud G., De LermaBarbaro A., Nicolis M., Cestari T., Ramarli D., Riviera A.P., Accolla R.S. Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells. J. Immunol. 156:1996;4254-4258.
36. Riley J.L., Westerheide S.D., Price J.A., Brown J.A., Boss J.M. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). Immunity. 2:1995;533-543.
37. Scholl T., Mahanta S.K., Strominger J.L. Specific complex formation between the type II bare lymphocyte syndrom-associated transactivators CIITA and RFX5. Proc. Natl. Acad. Sci. USA. 94:1997;6330-6334.
38. Sherman P.A., Basta P.V., Heguy A., Wloch M.K., Roeder R.G., Ting J.P.Y. The octamer motif is a B-lymphocyte-specific regulatory element of the HLA-DRA gene promoter. Proc. Natl. Acad. Sci. USA. 86:1989;6739-6743.
39. Sherman P.A., Basta P.V., Ting J.P.Y. Upstream DNA sequences required for tissue-specific expression of the HLA-DRA gene. Proc. Natl. Acad. Sci. USA. 84:1987;4254-4258.
40. Steimle V., Durand B., Barras E., Zufferey M., Hadam M.R., Mach B., Reith W. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9:1995;1021-1032.
41. Steimle V., Otten L.A., Zufferey M., Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 75:1993;135-146.
42. Steimle V., Reith W., Mach B. Major histocompatibility complex class II deficiency: a disease of gene regulation [Review]. Adv. Immunol. 61:1996;327-340.
43. Steimle V., Siegrist C.A., Mottet A., Lisowska-Grospierre B., Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 265:1994;106-109.
44. Ting J.P., Painter A., Zeleznik N.J., Macdonald L.G., Moore T.M., Brown A., Schwartz B.D. YB-1 DNA-binding protein represses interferon gamma activation of class II major histocompatibility complex genes. J. Exp. M. 179:1994;1605-1611.
45. Ting J.P.Y., Wright K.L., Chin K.C., Brickey W.J., Li G. The DMB promoter: delineation, in vivo footprint, transactivation and transdominant suppression. J. Immunol. 159:1997;5457-5462.
46. Vilen B.J., Cogswell J.P., Ting J.P. Stereospecific alignment of the X and Y elements is required for major histocompatibility complex class II DRA promoter function. Mol. Cell Biol. 11:1991;2406-2415.
47. Vilen B.J., Penta J.F., Ting J.P.Y. Structural constraints within a trimeric transcriptional regulatory region: constitutive and interferon-gamma inducible expression of the HLA-DRA gene. J. Biol. Chem. 267:1992;23728-23734.
48. Williams G.S. Mice lacking the transcription factor CIITA - a second look. Int. Immunol. 10:1998;1957-1967.
49. Wright K.L., Chin K.C., Linhoff M., Skinner C., Brown J.A., Boss J.M., Stark G.R., Ting J.P.Y. CIITA stimulation of transcription factor binding to MHC class II and associated promoters in vivo. Proc. Natl. Acad. Sci. USA 95. 95:1998;6267-6272.
50. Wright K.L., Ting J.P. In vivo footprint analysis of the HLA-DRA gene promoter: Cell-specific interaction at the octamer site and up-regulation of X box binding by interferon gamma. Proc. Natl. Acad. Sci. USA. 89:1992;7601-7605.
51. Wright K.L., Vilen B.J., Itoh-Lindstrom Y., Moore T.L., Li G., Criscitiello M., Cogswell P., Clarke J.B., Ting J.P.Y. CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors. EMBO J. 13:1994;4042-4053.
52. Zeleznik-Le N.J., Itoh Lindstrom Y., Clarke J.B., Moore T.L., Ting J.P. The B cell-specific nuclear factor OTF-2 positively regulates transcription of the human class II transplantation gene DRA. J. Biol. Chem. 267:1992;7677-7682.
53. Zeleznik-Le N., Azizkhan J.C., Ting J.P.Y. Affinity-purified CCAAT-box-binding protein (YEBP) functionally regulates expression of a human class II major histocompatibility complex gene and the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA. 88:1991;1873-1877.
54. Zhou H., Glimcher L.H. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA one of the defective genes in type II MHC combined immune deficiency. Immunity. 2:1995;545-553.